LET001

LET001 is a preclinical-stage therapeutic candidate being developed by Harbour BioMed (HBMK) for the treatment of obesity. It utilizes the Lysosome-Targeting Chimera (LYTAC) modality, a form of targeted protein degradation (TPD) designed to induce the degradation of extracellular or membrane-bound proteins. LYTAC molecules typically function by simultaneously binding a target protein and a cell-surface lysosome-shuttling receptor, such as the cation-independent mannose-6-phosphate receptor (CI-M6PR), thereby dragging the target into the endosomal-lysosomal pathway for destruction. While the specific molecular target of LET001 remains undisclosed, the program represents an application of protein degradation technology to metabolic disease management.